Strategic Insights for Pharma Leaders
Between 2025 and 2030, over $300bn in prescription drug revenues will lose exclusivity. This is positive news for patients and healthcare budgets but represents a challenge for the pharma companies who need to retain positive growth. Every company is facing a unique set of circumstances and will need a tailored approach that combines dealmaking, lifecycle management and enhanced launch strategies.
Our new report digs into the latest loss of exclusivity data, and reveals practical portfolio tactics, growth gap analysis, and strategic models shaping the future of pharma, biotech, and investment.
Key Insights:
- Patent Cliff Impact: See which top brands and blockbusters are expiring.
- Growth Gap Forecasts: Discover how large pharma’s growth gap will hit $94bn by 2030, and who’s best placed to close it.
- Strategy Archetypes: Review proven tactics, from future-proofing and bolt-on deals to transformational M&A and portfolio refocusing.
- Case Studies: Learn from AbbVie’s Humira strategy and Sanofi/Regeneron’s Dupixent success.
